AxoGen
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +68.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 11.7% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth B
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 17.6% | Better than 79% |
| Net income CAGR (3Y) | -41.5% | Better than 6% |
| Free cash flow CAGR (3Y) | 31.0% | Better than 75% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 74.3% | Better than 86% |
| Operating margin | -3.5% | Better than 18% |
| Net margin | -7.0% | Better than 18% |
| Return on equity | -13.5% | Better than 18% |
| Return on invested capital | -4.3% | Better than 23% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 10.6% | Better than 90% |
| 6-month return | 36.3% | Better than 92% |
| 12-month return (ex latest month) | 36.5% | Better than 75% |
| Distance below 52-week high | 6.6% | Better than 91% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.1x | Better than 87% |
| Debt to assets | 30.5% | Better than 41% |
| Interest coverage | -1.0x | Better than 22% |
| Free cash flow / net income | 102.6% | Better than 40% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 4.4% | Better than 8% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 56.35
- Open
- 55.71
- Day range
- 55.03 - 56.91
- Avg price
- 55.76
- Volume
- 876.07K
- Turnover
- 48.85M
- Turnover ratei
- 1.60%
- Volume ratioi
- 0.61
- Amplitudei
- 3.34%
- 52-week rangei
- 26.92 - 59.72
Valuation
- P/Ei
- -163.97
- P/E (TTM)i
- -88.49
- P/Bi
- 6.71
- EPSi
- -0.34
- Book value / shi
- 8.31
- Net profit
- -20.31M
- Net assets
- 496.12M
Share structure
- Market cap
- 3.33B
- Float capi
- 3.04B
- Shares out
- 59.73M
- Float sharesi
- 54.61M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
6.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-9.46M net over the window
Short interest
- Shares short
- 6.99M
- % of floati
- 11.71%
- Days to coveri
- 3.28
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of AxoGen (AXGN)?
AxoGen last traded at 55.75. This page shows a periodic quote snapshot. Check the displayed quote time.
What is AxoGen's market cap?
About 3.33B.
What is the P/E ratio of AxoGen?
The trailing twelve-month P/E is -88.49. The Valuation tab shows it against the stock's own five-year range.
Does AxoGen pay a dividend?
AxoGen does not currently pay a regular dividend.
Is AxoGen a buy according to analysts?
The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 58.18, which implies 4.4% upside from the current price. This is not investment advice.
What is AxoGen's StockVane Quant Rating?
The StockVane Momentum strategy currently rates AxoGen a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
AxoGen discussion 0 comments